Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Astrocytoma
New astrocytoma research reported from B. Neyns and co-authors
April 29th, 2008
According to recent research from Brussels, Belgium, "Dose-dense temozolomide schedules deplete O-6-methylguanine methyltransferase and may overcome chemoresistance. This multicenter cohort study enrolled 19 patients (15 anaplastic astrocytoma, 4 anaplastic oligoastrocytoma) who received temozolomide (100 mg/m(2)/day for 21 consecutive days every 28-day cycle) at first recurrence, either until disease progression or 12 cycles." "Six-month progression-free survival was 56%, comparing favorably with historic controls treated with the standard 5-day temozolomide schedule. Median survival was 12.9 months (95% CI: 3.7, 22 months). Among 15 evaluable patients, 2 had a...
Source: Cancer Weekly (2008-04-29)
|
